Linezolid: Nursing Drug Guide, Serotonin Syndrome & NCLEX Review
Oxazolidinone antibiotic for resistant Gram-positive infections—on shift, the highest-stakes nursing failures are giving linezolid while serotonergic antidepressants, tramadol, or MAOIs remain active, and missing early serotonin syndrome, myelosuppression, or optic neuropathy during prolonged courses.
Linezolid is a reversible monoamine oxidase inhibitor. Fatal serotonin syndrome has been reported with SSRIs and other serotonergic drugs. Do not give linezolid to patients taking MAOIs or within two weeks of an MAOI. Before every dose, reconcile home and MAR medications for serotonergic antidepressants, triptans, meperidine, and sympathomimetics. Monitor for hyperthermia, rigidity, myoclonus, autonomic instability, and agitation progressing to delirium. Weekly CBC is required—especially beyond 14 days—because myelosuppression and optic neuropathy increase with prolonged use (controlled trials evaluated courses up to 28 days).
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first linezolid dose: complete medication reconciliation for MAOIs, SSRIs/SNRIs, triptans, tramadol, and sympathomimetics; hold and clarify any prohibited combination. During therapy, trend weekly CBC and mental status—new agitation with hyperthermia on linezolid means stop the dose and escalate for serotonin syndrome, not “wait for rounds.”
Most common brand names
Linezolid is available as generic tablets, oral suspension, and ready-to-use IV infusion bags. Verify oral versus IV route—doses are interchangeable mg-for-mg when switching routes per labeling.
Common brand name: Zyvox (tablet, oral suspension, and IV injection). Do not confuse with other antibiotics ending in “-zolid” or look-alike IV bags on the unit.
Why we give it — Indications
Linezolid treats susceptible Gram-positive infections when other agents are limited—nurses most often see it for resistant skin infections, pneumonia, and vancomycin-resistant Enterococcus in complex or sepsis pathways. It is not for Gram-negative coverage alone.
| Use | Detail |
|---|---|
| Nosocomial pneumonia | Adults/adolescents ≥12 years: 600 mg IV or oral every 12 hours for 10–14 days per Table 1 labeling. |
| Community-acquired pneumonia | Same adult/adolescent regimen; treat concurrent bacteremia per infectious-disease plan. |
| Complicated skin / soft tissue | Includes diabetic foot infection without osteomyelitis; adults 600 mg q12h; duration 10–14 days (up to 28 days for VRE per labeling). |
| Complicated cellulitis / MRSA-type coverage | Used when susceptibility confirms Gram-positive pathogens; ensure Gram-negative therapy if mixed infection suspected. |
| Vancomycin-resistant E. faecium (VRE) | 600 mg q12h for 14–28 days including bacteremia; coordinate blood cultures and source control. |
| Uncomplicated skin infection | Adults: 400 mg oral every 12 hours for 10–14 days; MSSA or S. pyogenes per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Limitations: Not indicated for Gram-negative infections—initiate appropriate Gram-negative therapy if documented or suspected. Safety and efficacy beyond 28 consecutive days have not been evaluated in controlled trials.
How it works
Linezolid binds the bacterial 23S ribosomal RNA of the 50S subunit and inhibits protein synthesis. It is bacteriostatic against enterococci and staphylococci and bactericidal against most streptococci. Uniquely among many antibiotics, linezolid also acts as a reversible, nonselective monoamine oxidase inhibitor—that pharmacology drives serotonin syndrome, interaction with adrenergic agents, and dietary tyramine precautions, not just antimicrobial effect.
Dosing overview
Confirm indication, weight (pediatrics), and route against current prescribing information. No dose adjustment is required when switching IV to oral at the same mg dose and interval.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for the next scheduled dose, especially near end of infusion windows.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Half-life (adults) | Approximately 5–7 hours (labeling pharmacokinetics) | Steady state within several doses; interaction monitoring continues 24 h after last dose when serotonergic drugs were stopped |
| Oral bioavailability | ~100% | IV-to-oral switch without mg dose change when clinically stable |
| IV administration time | 30–120 minutes | Use pump; flush line if shared; check incompatibilities |
| MAOI activity | Reversible inhibition of MAO-A and MAO-B | Explains serotonin syndrome and tyramine/sympathomimetic interactions—not optional counseling |
| Duration limit (trials) | Evaluated up to 28 consecutive days | Longer courses need ID/specialist plan with CBC and vision monitoring |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Complete medication reconciliation for MAOIs (including within 2 weeks), SSRIs/SNRIs, sertraline or other antidepressants, triptans, tramadol, meperidine, bupropion, buspirone, and sympathomimetic decongestants
- Review allergy history to linezolid; confirm indication and that Gram-negative therapy is ordered if needed
- Baseline CBC; plan weekly CBC—more often if therapy >2 weeks, renal/hepatic impairment, or myelosuppressive co-drugs
- Assess blood pressure history, tyramine-rich diet, and home SSRI adherence; verify oral vs IV route and infusion time on MAR
Contraindications
- Known hypersensitivity to linezolid or formulation components
- Patients taking any MAOI or within two weeks of taking an MAOI (e.g., phenelzine, isocarboxazid) per labeling
- Unless carefully observed and alternatives are unavailable: carcinoid syndrome; concurrent serotonergic agents (SSRIs, TCAs, triptans, meperidine, etc.) per warnings
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| SSRIs / SNRIs / serotonergic opioids | Serotonin syndrome (fatal cases reported) | Hold linezolid until pharmacy documents plan; stop serotonergic drug when linezolid is urgent; monitor 2 weeks (5 weeks after fluoxetine) or 24 h after last linezolid dose |
| MAOIs | Contraindicated combination | Verify 2-week washout; never administer together |
| Sympathomimetics / vasopressors | Enhanced pressor response; hypertensive risk | Coordinate with pharmacy; avoid pseudoephedrine-containing cold products unless approved |
| High tyramine foods | Pressor response at large tyramine doses (>100 mg in studies) | Teach to avoid large amounts of aged cheese, fermented meats, tap beers, red wine per labeling |
| Myelosuppressive drugs | Additive cytopenias | Weekly CBC; hold if platelets/neutrophils fall substantially |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: 600 mg tablet or 100 mg/5 mL suspension—may give with or without food. Shake suspension after constitution; use within 21 days per labeling.
IV: Administer by infusion over 30 to 120 minutes using IV infusion pump setup. Inspect bag for particulates and leaks; do not add drugs to the bag. If the same line is used sequentially, flush per compatibility guidance. Y-site incompatibilities include amphotericin B, chlorpromazine, diazepam, phenytoin, and trimethoprim-sulfamethoxazole; chemical incompatibility with ceftriaxone per labeling.
- Document infusion start/stop and exact product strength (2 mg/mL bags)
- When clinically stable, oral conversion uses the same mg dose—verify pharmacy switches both route and MAR
- Do not use infusion bags in series connections; discard unused portion
Because linezolid is an MAOI-class drug, nurses must treat new SSRI or tramadol orders as a hard stop until prescriber and pharmacy reconcile risk—not as a “pharmacy will catch it later” problem.
Expected therapeutic response
- Defervescence and improving clinical status in pneumonia or fever when source control and susceptibilities align
- Decreasing local erythema, drainage, or pain in treated skin/soft-tissue infection
- Negative follow-up blood cultures in VRE bacteremia when source controlled
- Stable CBC, mental status, and blood pressure while on therapy—any serotonin or cytopenia cue requires reassessment before the next dose
Red flags — Stop and act
Serotonin syndrome and hematologic toxicity can escalate quickly. Hold linezolid and escalate immediately.
- Serotonin syndrome cues: Agitation, confusion, hyperthermia, rigidity, myoclonus, autonomic instability—especially with SSRIs, tramadol, or triptans on the MAR
- Severe hypertension after sympathomimetic or high tyramine exposure
- Platelet count substantially below baseline, neutropenia, or pancytopenia on weekly CBC
- Blurred vision, color-vision change, or visual field defect (possible optic neuropathy)—urgent ophthalmology per labeling
- Recurrent nausea/vomiting with acidosis or low bicarbonate suggesting lactic acidosis
- Anaphylaxis, severe rash, or Stevens-Johnson syndrome / toxic epidermal necrolysis
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Diarrhea, headache, nausea | Common in clinical trials (oral and IV) | Supportive care; distinguish from C. difficile colitis or lactic acidosis if persistent or severe |
| Myelosuppression (anemia, leukopenia, thrombocytopenia) | Reported; more thrombocytopenia with renal/hepatic impairment | Weekly CBC; hold and notify if counts fall substantially |
| Peripheral / optic neuropathy | Primarily >28 days; vision loss reported with extended use | Stop and notify; ophthalmic evaluation for visual symptoms |
| Serotonin syndrome | Postmarketing fatalities with serotonergic co-therapy | Hold linezolid and serotonergic agents; urgent escalation |
| Lactic acidosis | Reported with recurrent nausea/vomiting | Hold dose; evaluate bicarbonate/lactate per protocol |
| Convulsions, rhabdomyolysis, hypoglycemia | Warnings in labeling | Monitor glucose in at-risk patients; assess neuro and muscle symptoms |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Not specified in the reviewed prescribing information for a maximum human overdose dose. Animal studies noted decreased activity and ataxia at very high exposures.
Management
Supportive care with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination—approximately 30% of a dose removed during a 3-hour session beginning 3 hours post-dose in a Phase 1 study. Data are not available for peritoneal dialysis or hemoperfusion. No specific antidote is listed in the reviewed prescribing information.
Look-alike / sound-alike and error prevention
- Linezolid vs vancomycin—both used for resistant Gram-positive infections; different monitoring (trough vs CBC/serotonin)
- Linezolid vs linezolid brand “Zyvox”—verify 600 mg vs 400 mg strength for indication
- Oral suspension vs IV bag—both 600 mg doses but different administration checks
- Antibiotic continued while home SSRI still filled—reconciliation error, not a dispensing typo
- Duplicate therapy—linezolid plus another agent with MAOI activity without documented plan
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Serotonergic MAR scan | Flag SSRIs, SNRIs, tramadol, triptans, and MAOIs on every shift until linezolid stops |
| CBC cadence | Weekly minimum; more vigilance after day 14 and in renal/hepatic impairment |
| Diet teaching | Avoid large tyramine-rich meals; moderate diet usually acceptable—follow labeling patient counseling |
| IV line | 30–120 min infusion; flush shared lines; never bolus push |
| Commonly missed | Home SSRI continued; cold medicine with pseudoephedrine; no CBC ordered after week 2 |
| Ask pharmacy when | Urgent linezolid needed on SSRIs, prolonged course >28 days, cytopenias, or Y-site compatibility questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Patients on serotonergic antidepressants or opioids | Highest serotonin syndrome risk—linezolid only if alternatives unavailable and monitoring plan documented per labeling |
| Severe renal or moderate–severe hepatic impairment | More thrombocytopenia reported—intensify CBC monitoring |
| Therapy >28 days | Neuropathy and optic toxicity risk; controlled data limited beyond 28 days |
| Uncontrolled hypertension / pheochromocytoma | Avoid sympathomimetics and monitor BP closely per warnings |
| Pregnancy | Available data have not identified a major birth-defect signal; use only if benefit justifies risk per labeling |
| Lactation | Present in breast milk (~6–9% of infant dose); LactMed: not a reason to stop breastfeeding but monitor infant for diarrhea/vomiting |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Weekly CBC (more often if >2 weeks therapy, cytopenias, or myelosuppressive co-drugs)
- Mental status, temperature, muscle tone, and autonomic signs for serotonin syndrome
- Blood pressure, especially with decongestants or vasopressors
- Vision changes; formal eye monitoring if therapy ≥3 months or new visual symptoms per labeling
- Infection markers: fever trend, wound appearance, culture follow-up
Document
- MAOI/serotonergic reconciliation completed before first dose
- CBC dates/results and prescriber notification of abnormal values
- IV infusion duration, oral suspension administration, and route switches
- Patient teaching on tyramine-rich foods, cold medicines, and when to report agitation or vision changes
Patient teaching
- Take exactly as prescribed; complete the antibacterial course unless prescriber stops early for toxicity
- Do not start or stop antidepressants, pain medicines, or cold/decongestant products without prescriber approval while on linezolid
- Avoid large servings of aged cheeses, fermented meats, tap beers, and red wines; improper storage of protein-rich foods can increase tyramine per labeling
- Report agitation, confusion, high fever, stiff muscles, fast heartbeat, severe headache, vision changes, unusual bleeding or bruising, or persistent vomiting immediately
- Breastfeeding patients: watch infant for diarrhea and vomiting; discuss risks and benefits with the prescriber
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to linezolid
- Active MAOI or MAOI within the prior two weeks
- Serotonergic drug (SSRI/SNRI, triptan, tramadol, meperidine, etc.) on MAR without documented urgent-use plan and monitoring
- Suspected serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability, altered mental status)
- Substantial fall in platelets or other CBC lines; worsening myelosuppression
- New visual symptoms, recurrent vomiting with suspected acidosis, or uncontrolled hypertension with prohibited sympathomimetic co-therapy
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Linezolid is often started urgently for resistant organisms while home psychiatric medications remain on the profile. Build MAOI-class interaction checks into admission reconciliation and every new medication order—not only the first dose.
1. Check-before-you-give protocol
- Right patient, dose (600 vs 400 mg), route, time—and right serotonergic/MAOI clearance
- Scan MAR and home list for SSRIs, tramadol, triptans, MAOIs, and sympathomimetics
- Confirm weekly CBC is ordered when therapy is expected beyond 1–2 weeks
- IV: verify 30–120 minute infusion programmed—not IV push
2. High-alert and safety badge
MAOI-class antibiotic — serotonin and CBC monitoring criticalMany institutions treat linezolid with SSRI co-therapy as a hard stop. Apply the same rigor as other high-risk medication workflows even when linezolid is not on a formal high-alert list.
3. Clinical workflow: hold and question rules
- If a new SSRI or tramadol order appears, hold linezolid until pharmacy/prescriber documents risk mitigation
- If temperature and rigidity rise with agitation, hold linezolid and activate serotonin-syndrome pathway before the next dose
- If platelets drop on weekly CBC, hold and request ID/pharmacy review before continuing
4. Critical teach-back questions
- “Which medicines must you avoid or ask about while taking linezolid?” (Patient should mention antidepressants, many pain medicines, and cold/decongestant products without prescriber approval.)
- “What symptoms mean you need help right away?” (Patient should name high fever, confusion, stiff muscles, vision changes, or easy bleeding.)
5. Care coordination
Pharmacist: Serotonergic interaction plans, MAOI washout timing, CBC review, IV compatibility, course length beyond 28 days
Prescriber / infectious disease: Indication duration, Gram-negative coverage, hold for toxicity, ophthalmology referral for visual symptoms
🧠 Quick mental checklist
- Is any serotonergic antidepressant, tramadol, triptan, or MAOI active on the MAR or home list?
- When was the last weekly CBC—and is therapy expected beyond 14 days?
- Any hyperthermia, rigidity, myoclonus, or agitation since the last dose?
- For IV: is the infusion programmed for 30–120 minutes, not bolus?
- Has the patient started a cold medicine or large tyramine-rich meal pattern?
Linezolid NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for linezolid MAOI-class and serotonin safety using a tabbed inpatient case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), post-hold trend interpretation, documentation cloze, ordered response, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Linezolid 600 mg IV q12h — 0800 dose given; next due 2000
- Sertraline 100 mg daily — given 0900 (home SSRI continued on MAR)
- Tramadol 50 mg PO q6h PRN — given 1400 for wound pain (2 doses in 24 h)
- 0.9% NaCl IV 100 mL/h maintenance
- Admission platelets 210 × 10³/µL; WBC 11.2 × 10³/µL
- Day 7 (prior week): platelets 168 × 10³/µL
- Today (day 4 of linezolid): platelets 142 × 10³/µL; WBC 9.8 × 10³/µL
- Weekly CBC due tomorrow per protocol
- 58-year-old with VRE bacteremia from central access; day 4 of linezolid
- Long-standing depression on sertraline; no documented MAOI washout note
- History of hypertension; takes amlodipine at home
- No known linezolid allergy
- Temp 39.0 °C; HR 118; BP 168/94
- Patient agitated, picking at lines; reports stiff legs and shivering
- Hyperreflexia noted; no focal neuro deficit documented
- Family states patient “has not been this confused since admission”
Answer key & rationale
Frequently asked questions
Why is linezolid dangerous with SSRIs or tramadol?
Linezolid is a reversible monoamine oxidase inhibitor. Co-administration with serotonergic antidepressants, triptans, meperidine, or other serotonergic agents can cause serotonin syndrome, including fatal cases. Labeling advises stopping serotonergic drugs before linezolid when possible and monitoring for hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes if both are required.
How often should nurses monitor CBC on linezolid?
Prescribing information recommends weekly complete blood counts in patients receiving linezolid, especially when therapy exceeds two weeks, when myelosuppression is pre-existing, with renal or hepatic impairment, or with other bone-marrow-suppressing drugs. Hold and notify the prescriber if platelets or other cell lines fall substantially.
When should a nurse hold linezolid?
Hold for known hypersensitivity, active MAOI use or use within two weeks of an MAOI, suspected serotonin syndrome, uncontrolled hypertension with prohibited sympathomimetic co-therapy, worsening myelosuppression, new visual symptoms suggesting optic neuropathy, recurrent vomiting with acidosis suggesting lactic acidosis, or orders exceeding 28 days without specialist plan.
Can linezolid be given IV and switched to oral?
Yes. Labeling states no dose adjustment is necessary when switching from IV to oral administration at the same mg dose and interval. IV linezolid must infuse over 30 to 120 minutes; do not use Y-site combinations listed as incompatible without pharmacy review.
Is linezolid safe during pregnancy and breastfeeding?
Available human data have not identified a major birth-defect signal; use in pregnancy only if benefit justifies risk per labeling. Linezolid is present in breast milk at an estimated 6% to 9% of the therapeutic infant dose; LactMed states maternal linezolid is not a reason to discontinue breastfeeding but infants should be monitored for diarrhea and vomiting.
What is the antidote for linezolid overdose?
No specific antidote is listed in the reviewed prescribing information. Management is supportive with maintenance of glomerular filtration; hemodialysis may facilitate more rapid elimination because approximately 30% of a dose was removed during a 3-hour session in a Phase 1 study.
References
- U.S. National Library of Medicine. ZYVOX (linezolid) injection, tablets, and oral suspension — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e70e63b-bfd5-478d-a8ee-8ba22c9efabd
- U.S. National Library of Medicine. Linezolid — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a605005.html
- Drugs and Lactation Database (LactMed). Linezolid. Bethesda (MD): National Institute of Child Health and Human Development; updated July 15, 2024.https://www.ncbi.nlm.nih.gov/books/NBK501700/
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.accessdata.fda.gov/scripts/medwatch/
- National Library of Medicine. Drugs and Lactation Database (LactMed) — About and peer review. NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK501922/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.